Abstract
Purpose
To identify the role of epithelial cellular adhesion molecule (EpCAM) in gastric cancer growth and explore the potential value of EpCAM monoclonal antibody as new therapeutic strategy for gastric cancer.
Methods
The expression of EpCAM was determined by immunohistochemistry staining in gastric cancer tissues, RT-PCR and Western blot in cell lines. EpCAM expression in cell lines was downregulated by small interfering RNA. Then the effects of EpCAM on gastric cancer cell growth in vivo and in vitro were determined by MTT, FCM analysis, clone formation assay and tumor formation assay. Additionally, western blot was used to detect the effect of EpCAM on cell cycle-relevant factor cyclin D1.
Results
EpCAM was found to be overexpressed in gastric cancer tissues and cell lines. Downregulation of EpCAM resulted in a decrease of cell proliferation and cell cycle arrest in AGS and SGC7901 cells, which had high endogenous EpCAM expression. EpCAM downregulation also suppressed tumor formation in nude mice. Moreover, EpCAM repression in gastric cancer cells could downregulate cyclin D1.
Conclusions
EpCAM was a potential oncogene and contributed to the growth of gastric cancer. Our data first provided compelling evidence of potential value of EpCAM in the therapy of gastric cancer in clinic.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96:417–423. doi:10.1038/sj.bjc.6603494
Balzar M, Winter MJ, de Boer CJ et al (1999) The biology of the 17–1A antigen (Ep-CAM). J Mol Med 77:699–712. doi:10.1007/s001099900038
Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. doi:10.1056/NEJMoa050434
Calabrese G, Crescenzi C, Morizio E et al (2001) Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet 92:164–165. doi:10.1159/000056891
Chaudry MA, Sales K, Ruf P et al (2007) EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 96:1013–1019. doi:10.1038/sj.bjc.6603505
Generali D, Berruti A, Brizzi MP et al (2006) Hypoxiainducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12:4562–4568. doi:10.1158/1078-0432.CCR-05-2690
Gladden AB, Diehl JA (2005) Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 96:906–913. doi:10.1002/jcb.20613
Gulubova MV (2002) Expression of cell adhesion molecules, their ligands and tumour necrosis factoralpha in the liver of patients with metastatic gastrointestinal carcinonoms. Histochem J 34:67–77. doi:10.1023/A:1021304227369
Hartung G, Hofheinz RD, Dencausse Y et al (2005) Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 28:347–350. doi:10.1159/000084595
Kaminishi M (2005) Diversity of gastric cancinogenesis. Oncology 69:1–8. doi:10.1159/000086624
Münz M, Kieu C, Mack B et al (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748–5758. doi:10.1038/sj.onc.1207610
Osada S, Kanematsu M, Imai H et al (2008) Hepatic fibrosis influences the growth of hepatocellular carcinoma. Hepatogastroenterology 55:184–187
Osta WA, Chen Y, Mikhitarian K et al (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–5824. doi:10.1158/0008-5472.CAN-04-0754
Pantel K, Woelfle U (2005) Detection and molecular characterization of disseminated tumour cells: implication for anticancer therapy. Biochim Biophys Acta 1756:53–64
Ploverini PJ (1996) Cellular adhesion molecules: newly identified mediators of angiogenesis. Am J Pathol 148:1023–1029
Punt CJ, Nagy A, Douillard JY et al (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomized study. Lancet 360:671–677. doi:10.1016/S0140-6736(02)09836-7
Riethmüller G, Schneider-Gädicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke’s C colorectal carcinoma. Lancet 343:1177–1183. doi:10.1016/S0140-6736(94)92398-1
Seligson DB, Pantuck AJ, Liu X et al (2004) Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10:2659–2669. doi:10.1158/1078-0432.CCR-1132-03
Songun I, Litvinov SV, van de Velde CJ et al (2005) Loss of Ep-CAM (CO17–1A) expression predicts survival in patients with gastric cancer. Br J Cancer 92:1767–1772. doi:10.1038/sj.bjc.6602519
Spizzo G, Obrist P, Ensinger C et al (2002) Prognostic significance of Ep-CAM and Her-2/neu overexpression in invasive breast cancer. Int J Cancer 98:883–888. doi:10.1002/ijc.10270
Trebak M, Begg GE, Chong JM et al (2001) Oligomeric state of the colon carcinoma-associated glycoprotein GA733–2 (EPCAM/EGP40) and its role in GA733-mediated homotypic cell-cell adhesion. J Biol Chem 276:2299–2309. doi:10.1074/jbc.M004770200
Trzpis M, McLaughlin PM, de Leij LM et al (2007) Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171:386–395. doi:10.2353/ajpath.2007.070152
Varga M, Obrist P, Schneeberger S et al (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10:3131–3136. doi:10.1158/1078-0432.CCR-03-0528
Went P, Vasei M, Bubendorf L et al (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128–135. doi:10.1038/sj.bjc.6602924
Xie X, Wang CY, Cao YX et al (2005) Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 11:344–347
Acknowledgments
This work was supported by grants from National Natural Science Foundation of China (No. 30670969). We also thank Technician Taidong Qiao and Chen Zhen for their excellent technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wenqi, D., Li, W., Shanshan, C. et al. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol 135, 1277–1285 (2009). https://doi.org/10.1007/s00432-009-0569-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0569-5